Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
Total Valuation
Axsome Therapeutics has a market cap or net worth of $5.25B. The enterprise value is $5.08B.
Market Cap$5.25B
Enterprise Value$5.08B
Share Statistics
Axsome Therapeutics has 49,901,485 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding49,901,485
Owned by Insiders1.37%
Owned by Institutions0.53%
Financial Efficiency
Axsome Therapeutics’s return on equity (ROE) is -5.04 and return on invested capital (ROIC) is -82.14%.
Return on Equity (ROE)-5.04
Return on Assets (ROA)-0.51
Return on Invested Capital (ROIC)-82.14%
Return on Capital Employed (ROCE)-0.83
Revenue Per Employee541.70K
Profits Per Employee-403.39K
Employee Count712
Asset Turnover0.68
Inventory Turnover2.12
Valuation Ratios
The current PE Ratio of Axsome Therapeutics is ―. Axsome Therapeutics’s PEG ratio is -1.03.
PE Ratio―
PS Ratio10.51
PB Ratio71.10
Price to Fair Value71.10
Price to FCF-31.50
Price to Operating Cash Flow-42.46
PEG Ratio-1.03
Income Statement
In the last 12 months, Axsome Therapeutics had revenue of 385.69M and earned -287.22M in profits. Earnings per share was -5.99.
Revenue385.69M
Gross Profit352.39M
Operating Income-280.56M
Pretax Income-287.13M
Net Income-287.22M
EBITDA-272.60M
Earnings Per Share (EPS)-5.99
Cash Flow
In the last 12 months, operating cash flow was -120.63M and capital expenditures 120.00K, giving a free cash flow of -120.51M billion.
Operating Cash Flow-120.63M
Free Cash Flow-120.51M
Free Cash Flow per Share-2.41
Dividends & Yields
Axsome Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.99
52-Week Price Change26.20%
50-Day Moving Average105.89
200-Day Moving Average105.43
Relative Strength Index (RSI)57.29
Average Volume (3m)607.39K
Important Dates
Axsome Therapeutics upcoming earnings date is Nov 10, 2025, Before Open (Confirmed).
Last Earnings DateAug 4, 2025
Next Earnings DateNov 10, 2025
Ex-Dividend Date―
Financial Position
Axsome Therapeutics as a current ratio of 2.11, with Debt / Equity ratio of 294.62%
Current Ratio2.11
Quick Ratio2.04
Debt to Market Cap0.04
Net Debt to EBITDA0.45
Interest Coverage Ratio-42.71
Taxes
In the past 12 months, Axsome Therapeutics has paid 85.00K in taxes.
Income Tax85.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Axsome Therapeutics EV to EBITDA ratio is -14.42, with an EV/FCF ratio of -30.55.
EV to Sales10.19
EV to EBITDA-14.42
EV to Free Cash Flow-30.55
EV to Operating Cash Flow-30.62
Balance Sheet
Axsome Therapeutics has $303.02M in cash and marketable securities with $215.29M in debt, giving a net cash position of -$87.72M billion.
Cash & Marketable Securities$303.02M
Total Debt$215.29M
Net Cash-$87.72M
Net Cash Per Share-$1.76
Tangible Book Value Per Share-$0.04
Margins
Gross margin is 91.48%, with operating margin of -72.74%, and net profit margin of -74.47%.
Gross Margin91.48%
Operating Margin-72.74%
Pretax Margin-74.45%
Net Profit Margin-74.47%
EBITDA Margin-70.68%
EBIT Margin-72.74%
Analyst Forecast
The average price target for Axsome Therapeutics is $165.53, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$165.53
Price Target Upside52.21% Upside
Analyst ConsensusStrong Buy
Analyst Count17
Revenue Growth Forecast69.83%
EPS Growth Forecast22.16%